ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,629 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentHorgenNumab Therapeutics AG
Numab Therapeutics AG Logo
Verified· 3 sourcesTrust Score
Summary

About the company

The core activity of Numab Therapeutics AG is the development and research of immunological and immuno-oncological drugs, in particular multispecific biotherapeutics. The company focuses on the development of next-generation drugs and platforms for the treatment of diseases, specializing in the development of proprietary technologies such as λ-Cap and MATCH.

AI-generated
Offering

Products & services

Industry:Research & Development
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

Numab Therapeutics AG

Pharmaceutical Industry
✓ Offered4
Development of multispecific antibody-based immunotherapies
Development of multispecific antibody-based immunotherapies for inflammation and cancer, using proprietary platforms λ-Cap™ and MATCH™ as well as in-house research and development programs.
Antibody discovery and engineering platform (λ-Cap™ / MATCH™)
Proprietary platform for antibody discovery, stabilization and engineering of mono- and multispecific therapeutics with modular assembly, high stability and a reproducible process.
Pipeline of clinical and preclinical drug programs
Own pipeline with programs in research, preclinical and clinical development for immunology, immuno-oncology, respiratory diseases, CNS and solid tumors.
Partnerships for preclinical and clinical development
Licensing, co-development and collaboration projects with pharma and biotech partners to fund and further develop multispecific antibody programs.
Trust & reputation

ranQ Trust Score of Numab Therapeutics AG: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 58% · As of October 2026

Without public customer reviews the score stays capped.

Numab Therapeutics AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Numab Therapeutics AG scores 88.5 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.86.512%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.90.07%
Numab Therapeutics AG scores 86.7 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).86.722%
Numab Therapeutics AG scores 60.2 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.97.14%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.23.34%
Qualifications+0.00

Numab Therapeutics AG reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

January 9, 2025Media
Numab raises additional CHF50 million
startupticker.ch
May 28, 2024Media
Johnson & Johnson acquires Numab spin-off for USD 1.25 billion
startupticker.ch

Knowledge

No knowledge articles yet

Once Numab Therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Numab Therapeutics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Numab Therapeutics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Numab Therapeutics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Bachtobelstrasse 5
8810 Horgen

At a glance

Legal form
Corporation
UID
CHE-199.155.103
Founded
2016 · 10 years
Last commercial register change
July 20, 2026
Employees
51 to 100
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    CA
    CDR-Life AG
    Horgen
    MA
    Mabylon AG
    Schlieren
    NS
    Neurimmune Subone AG
    Schlieren
    PA
    Philochem AG
    Otelfingen
    AB
    Araris Biotech AG
    Au Zh
    CR
    Charles River Laboratories Switzerland AG
    Hettlingen
    NA
    Neurimmune AG
    Schlieren
    AA
    Athebio AG
    Schlieren